Bristol Raises Guidance on Demand for Eliquis, New Drugs
Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by demand for the blood-thinner Eliquis and several newer treatments.Adjusted ...
Bristol Myers earnings beat expectations, driven by sales of older drugs
Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...
Kiplinger1y
Medicare Lists First 10 Drugs for Talks On Lowering Your Costs
Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp/NovoLog. They accounted for $50.5 billion in total Part D covered prescription drug costs from June ...